Published On: Tue, Jul 20th, 2021
World | By

Vaccine Makers Face Fresh Challenges as COVID Variants Weaken Vaccine Efficacyon July 20, 2021 at 9:04 am Save 10% on Citrus trees with code CITRUS
Share This

Scientists have already started looking for new vaccine candidates for the CCP virus as the mRNA vaccines, such as Pfizer and Moderna, become less effective against increasingly contagious coronavirus mutations, according to new research. The report, published in the U.S.-based New England Journal of Medicine at the beginning of July found that vaccine-induced antibodies were 2.9 times less able to neutralise the Delta strain, and 6.8 times less able to neutralise the Kappa strain. This comes down to the mutations in Delta and Kappa’s spike protein, which diminish the ability of vaccine-induced antibodies that protect the body from the virus. However, the research also noted that the antibodies will be strong enough in many people to block the virus at least three months after the second dose of the mRNA vaccines. Mehul Suthar, the study’s co-author and assistant professor at the Emory Vaccine Center, said these findings “provide some reassurance” that …

About the Author